Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

The global coronavirus immunoassay market continues to witness steady growth, reaching USD 3.7 billion in 2021 and is projected to exceed USD 6.9 billion by 2032, expanding at a CAGR of 5.5% during ...

The company also reported that its fourth quarter revenues dropped 7 percent from a year ago, while full-year 2024 revenues declined 3 percent.

Pharmaceutical company sponsorship of diagnostic testing remains an area with a gaping divide between the views of regulators and industry, ...

According to Research by SNS Insider, Point-of-Care Diagnostics Market Growth is Fueled by Technological Advancements and Rising Prevalence of Chronic DiseasesPune, March 21, 2025 (GLOBE NEWSWIRE) -- ...

Idexx's financial health is strong. The firm had historically funded its expansions and acquisitions primarily through its own cash generation and held virtually no long-term debt until 2014. Unlike ...

We have written at length about the U.S. Food and Drug Administration’s (FDA’s) actions to promulgate regulations specifying the agency’s authority ...

The global cell based assays market was projected to attain US$ 20.2 billion in 2023. It is anticipated to garner a 6.4% CAGR from 2024 to 2034, and by 2034, the market is likely to attain US$ 40.4 ...

MANILA, Philippines — Biologists at the University of the Philippines (UP) College of Science have developed an alternative and more cost-effective rapid test for ... based assay for the ...